Jody A. Charnow

Sclerotic class biopsy and serum creatinine levels at baseline, the end of induction, and after 12 months of treatment emerge as the best prognostic factors for advanced CKD.

The higher risk of hyponatremia among women vs men persisted regardless of diuretic type.

In a novel finding, living in the southeastern United States is an independent risk factor for new-onset CKD.

Investigators examined the risk of bone fracture associated with different forms of androgen deprivation therapy.

Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.

Investigators report findings from the MIRROR RCT trial, which compared pegloticase plus methotrexate vs placebo for uncontrolled gout.

Girls with glomerular disease have a 1.6-fold greater likelihood of experiencing a fracture of any type compared with girls in the general pediatric population, data show.

Persistent isolated C3 hypocomplementemia is associated with an increased risk for end-stage kidney disease or death in patients with proliferative lupus nephritis, a study revealed.

Latest findings from a study of RenalGuard contrast with those of previous randomized controlled trials.

Nearly 24% of patients with advanced CKD, including those on dialysis, have gout, according to a study.

New analysis suggests that gout prevalence is 21% among patients on peritoneal dialysis and 13% among those on hemodialysis.

New findings complement previous research showing no renoprotective effect of urate-lowering therapy in patients with chronic kidney disease.

Hyponatremia and hypernatremia in patients hospitalized for COVID-19 are associated with increased odds of adverse outcomes.

Gout prevalence in Veterans Affairs medical centers increased from 4.2% in 2005 to 5.8% in 2014.

Patients with asymptomatic hyperuricemia who achieved serum uric acid levels of 6.0 mg/dL or less while on urate-lowering therapy had fewer gout flare episodes, a study found.

Each 1 mg/dL rise in uric acid level was significantly associated with a 21% and 10% increased risk for cardiovascular and all-cause mortality, respectively, a study found.

Hyperuricemia and gout may be associated with a lower risk for Alzheimer disease.

Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.

Nearly two-thirds of hospitalized patients with COVID-19 and acute kidney injury requiring dialysis died during their hospital stay, a study found.

Lack of timely referrals to nephrologists contribute to racial and ethnic disparities in kidney disease care.

New study is the first to characterize pegloticase use in the dialysis population.

Nearly 52% of adult patients hospitalized for COVID-19 in the metropolitan New York region had hyponatremia or hypernatremia at admission, a study found.

Patients with new-onset lupus nephritis achieve significantly higher rates of complete response at 1, 2, and 3 years if they receive a higher initial dose of prednisone for remission induction, a study found.

Of 25 patients with both obesity and gout who had elevated uric acid levels prior to bariatric surgery, 10 achieved therapeutic target levels of uric acid at 12 months after the surgery, according to investigators.

Based on new findings from a study of patients with systemic lupus erythematosus, investigators suggest revising current guidelines to expand kidney biopsy indications to include isolated proteinuria of any grade.

A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.

Pooled analyses from 2 clinical trials show that voclosporin, a novel calcineurin inhibitor, is safe and effective in managing lupus nephritis.

Early data from a small ongoing trial shows that pegloticase, which is administered by injection, can result in substantial and sustained decreases in serum uric acid in kidney transplant recipients with treatment-refractory gout.

Patients with systematic lupus erythematosus who have a low platelet distribution width are more likely to have lupus nephritis.

Adding belimumab to standard therapy for lupus nephritis is associated with better renal outcomes compared with standard therapy alone.